As part of our In Profile series, unquote" takes a look at Vitruvian Partners' recent activity and what lies ahead for the UK-based GP.
Abénex draws capital from its Abénex V fund, which closed on €425m in December 2017
GP co-invests with VC Zobito and will combine the business with Verdane IX portfolio company Dapresy
Endless is currently investing from its Endless Fund IV, which held a final close on £525m
GP acquires a stake of up to 40% in the company via a capital increase of up to €120m